NASDAQ:QDEL QuidelOrtho (QDEL) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free QDEL Stock Alerts $47.94 -0.32 (-0.66%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$47.87▼$49.0850-Day Range$41.76▼$72.2552-Week Range$41.75▼$98.67Volume522,613 shsAverage Volume901,707 shsMarket Capitalization$3.20 billionP/E RatioN/ADividend YieldN/APrice Target$61.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get QuidelOrtho alerts: Email Address QuidelOrtho MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside28.5% Upside$61.60 Price TargetShort InterestHealthy3.65% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.76Based on 6 Articles This WeekInsider TradingAcquiring Shares$99,652 Bought Last QuarterProj. Earnings Growth61.87%From $2.57 to $4.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.95 out of 5 starsMedical Sector19th out of 939 stocksDiagnostic Substances Industry1st out of 13 stocks 4.0 Analyst's Opinion Consensus RatingQuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $61.60, QuidelOrtho has a forecasted upside of 28.5% from its current price of $47.94.Amount of Analyst CoverageQuidelOrtho has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.65% of the outstanding shares of QuidelOrtho have been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in QuidelOrtho has recently increased by 2.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQuidelOrtho has received a 49.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sexually transmitted diseases quick tests", "Lactose intolerance quick tests", and "Respiratory tract infection tests" products. See details.Environmental SustainabilityThe Environmental Impact score for QuidelOrtho is -2.61. Previous Next 2.6 News and Social Media Coverage News SentimentQuidelOrtho has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for QuidelOrtho this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,652.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for QuidelOrtho are expected to grow by 61.87% in the coming year, from $2.57 to $4.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is -299.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is -299.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About QuidelOrtho Stock (NASDAQ:QDEL)QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.Read More QDEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QDEL Stock News HeadlinesMarch 27, 2024 | stockhouse.comQDEL LOSS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELMarch 26, 2024 | prnewswire.comQDEL LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages QuidelOrtho Corporation Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - QDELMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 22, 2024 | markets.businessinsider.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELMarch 18, 2024 | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELMarch 16, 2024 | finance.yahoo.comQDEL Apr 2024 50.000 callMarch 16, 2024 | finance.yahoo.comQDEL Apr 2024 70.000 callMarch 16, 2024 | finance.yahoo.comQDEL Apr 2024 65.000 putMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 15, 2024 | markets.businessinsider.comROSEN, SKILLED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELMarch 14, 2024 | finance.yahoo.comQuidelOrtho to lay off employees after firing CEOMarch 12, 2024 | prnewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of QuidelOrtho Corporation - QDELMarch 9, 2024 | markets.businessinsider.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELMarch 7, 2024 | markets.businessinsider.comNATIONALLY RANKED ROSEN LAW FIRM Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELMarch 6, 2024 | seekingalpha.comQuidelOrtho: Uncertainty ReignsMarch 6, 2024 | businesswire.comQuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in CanadaMarch 6, 2024 | businesswire.comQuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in CanadaMarch 4, 2024 | markets.businessinsider.comAnalyst Scoreboard: 6 Ratings For QuidelOrthoMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of QuidelOrtho Corporation - QDELMarch 1, 2024 | prnewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELFebruary 29, 2024 | markets.businessinsider.comQuidelOrtho (QDEL) CEO Terminated After Reporting Dismal Q4 2023 Results - Hagens BermanFebruary 28, 2024 | businesswire.comQDEL LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDELFebruary 26, 2024 | businesswire.comQuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor ConferenceFebruary 26, 2024 | businesswire.comQuidelOrtho Corporation (QDEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of QuidelOrtho Corporation - QDELFebruary 23, 2024 | sg.finance.yahoo.comQuidelOrtho Corporation (QDEL) stock price, news, quote & history – Yahoo FinanceSee More Headlines Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today3/29/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:QDEL CUSIP74838J10 CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees7,100Year Founded1979Price Target and Rating Average Stock Price Target$61.60 High Stock Price Target$81.00 Low Stock Price Target$37.00 Potential Upside/Downside+28.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E Ratio18.65 P/E GrowthN/ANet Income$-10,100,000.00 Net Margins-0.34% Pretax Margin-0.97% Return on Equity5.54% Return on Assets3.21% Debt Debt-to-Equity Ratio0.45 Current Ratio1.57 Quick Ratio0.88 Sales & Book Value Annual Sales$3.00 billion Price / Sales1.07 Cash Flow$11.23 per share Price / Cash Flow4.27 Book Value$74.92 per share Price / Book0.64Miscellaneous Outstanding Shares66,850,000Free Float65,044,000Market Cap$3.20 billion OptionableOptionable Beta0.11 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Robert J. Bujarski J.D. (Age 55)Interim President, Executive VP & COO Comp: $2.62MMr. Joseph M. Busky CPA (Age 56)Chief Financial Officer Comp: $1.47MMs. Michelle A. Hodges (Age 63)Senior VP, General Counsel & Secretary Comp: $1.8MDr. Werner Kroll Ph.D. (Age 67)Senior Vice President of Research & Development Comp: $1.25MMr. Michael S. Iskra (Age 54)Interim CEO, Executive VP & Chief Commercial Officer Ms. Louise M. BrandyChief Information OfficerMr. Patrick E. KleinChief Administrative OfficerRuben ArguetaDirector of Investor RelationsMr. William J. Ferenczy (Age 68)Point of Care Business Unit Leader Ms. Tamara A. Ranalli (Age 51)Molecular Diagnostics Business Unit Leader More ExecutivesKey CompetitorsNeogenNASDAQ:NEOGIntellia TherapeuticsNASDAQ:NTLACelldex TherapeuticsNASDAQ:CLDXLantheusNASDAQ:LNTHMyriad GeneticsNASDAQ:MYGNView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 590 shares on 3/22/2024Ownership: 0.007%Vanguard Group Inc.Bought 44,770 shares on 3/11/2024Ownership: 7.242%Wellington Management Group LLPSold 132,222 shares on 3/5/2024Ownership: 0.940%Goldman Sachs Group Inc.Sold 57,873 shares on 3/1/2024Ownership: 0.383%American International Group Inc.Sold 2,845 shares on 2/28/2024Ownership: 0.100%View All Insider TransactionsView All Institutional Transactions QDEL Stock Analysis - Frequently Asked Questions Should I buy or sell QuidelOrtho stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares. View QDEL analyst ratings or view top-rated stocks. What is QuidelOrtho's stock price target for 2024? 7 brokers have issued 1 year price targets for QuidelOrtho's shares. Their QDEL share price targets range from $37.00 to $81.00. On average, they anticipate the company's stock price to reach $61.60 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price. View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts. How have QDEL shares performed in 2024? QuidelOrtho's stock was trading at $73.70 at the beginning of the year. Since then, QDEL stock has decreased by 35.0% and is now trading at $47.94. View the best growth stocks for 2024 here. When is QuidelOrtho's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our QDEL earnings forecast. How were QuidelOrtho's earnings last quarter? QuidelOrtho Co. (NASDAQ:QDEL) released its quarterly earnings data on Tuesday, February, 13th. The company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.01 by $0.84. The company earned $742.60 million during the quarter, compared to analyst estimates of $796.91 million. QuidelOrtho had a negative net margin of 0.34% and a positive trailing twelve-month return on equity of 5.54%. The company's revenue was down 14.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.74 EPS. What ETFs hold QuidelOrtho's stock? ETFs with the largest weight of QuidelOrtho (NASDAQ:QDEL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Ballast Small/Mid Cap ETF (MGMT) and Simplify Health Care ETF (PINK).iShares U.S. Medical Devices ETF (IHI). What guidance has QuidelOrtho issued on next quarter's earnings? QuidelOrtho issued an update on its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share guidance of 2.400-3.070 for the period, compared to the consensus EPS estimate of 5.070. The company issued revenue guidance of $2.8 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion. What is Doug Bryant's approval rating as QuidelOrtho's CEO? 47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM). Who are QuidelOrtho's major shareholders? QuidelOrtho's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.25%), Vanguard Group Inc. (7.24%), Senvest Management LLC (4.49%), Burgundy Asset Management Ltd. (1.74%), Rubric Capital Management LP (1.47%) and LGT Capital Partners LTD. (1.43%). Insiders that own company stock include Charles P Slacik, Joseph M Busky, Mary Lake Ph D Polan and William J Ferenczy. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QDEL) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.